Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.

Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.

Item
http://www.wikidata.org/entity/Q33405000
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphomaComparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy.Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma.CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
P2860

Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.

Item
http://www.wikidata.org/entity/Q33405000
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
@ast
Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
@en
type
label
Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
@ast
Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
@en
prefLabel
Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
@ast
Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P356
P1433
P1476
Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698